| Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency M Maillard, M Launay, B Royer, J Guitton, E Gautier‐Veyret, S Broutin, ... British journal of clinical pharmacology 89 (2), 762-772, 2023 | 17 | 2023 |
| Artificial increase of uracilemia during fluoropyrimidine treatment can lead to DPD deficiency misinterpretation F Thomas, M Maillard, M Launay, C Tron, MC Etienne-Grimaldi, ... Annals of Oncology 32 (6), 810-811, 2021 | 15 | 2021 |
| Additive effects of TPMT and NUDT15 on thiopurine toxicity in children with acute lymphoblastic leukemia across multiethnic populations M Maillard, R Nishii, W Yang, K Hoshitsuki, D Chepyala, SHR Lee, ... JNCI: Journal of the National Cancer Institute 116 (5), 702-710, 2024 | 11 | 2024 |
| PharmGKB summary: acyclovir/ganciclovir pathway M Maillard, L Gong, R Nishii, JJ Yang, M Whirl-Carrillo, TE Klein Pharmacogenetics and genomics 32 (5), 201-208, 2022 | 8 | 2022 |
| Diversity of dose-individualization and therapeutic drug monitoring practices of platinum compounds: a review M Maillard, F Le Louedec, F Thomas, E Chatelut Expert Opinion on Drug Metabolism & Toxicology 16 (10), 907-925, 2020 | 8 | 2020 |
| Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose … M Maillard, A Eche-Gass, M Ung, A Brice, S Marsili, M Montastruc, ... Cancer Chemotherapy and Pharmacology 87, 579-583, 2021 | 4 | 2021 |
| Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma M Maillard, C Chevreau, F Le Louedec, M Cassou, C Delmas, L Gourdain, ... Cancers 12 (12), 3647, 2020 | 4 | 2020 |
| Biological role of pazopanib and sunitinib aldehyde derivatives in drug-induced liver injury M Maillard, C Arellano, C Vachoux, C Chevreau, NJ Cabaton, F Pont, ... Metabolites 12 (9), 852, 2022 | 3 | 2022 |
| Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription M Maillard, B Louveau, P Vilquin, L Goldwirt, F Thomas, S Mourah Therapies 77 (2), 171-183, 2022 | 1 | 2022 |
| Etude des mécanismes impliqués dans l'hépato-toxicité des médicaments anti-cancéreux: exemples de la trabectedine et des inhibiteurs de tyrosine kinases M Maillard Université Paul Sabatier-Toulouse III, 2021 | 1 | 2021 |
| Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia Z Li, H Zhao, W Yang, M Maillard, S Yoshimura, YC Hsiao, X Huang, ... Nature Communications 16 (1), 1153, 2025 | | 2025 |
| Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity M Maillard, JQ Nguyen, W Yang, K Hoshitsuki, MV Relling, KE Caudle, ... Clinical Pharmacology & Therapeutics, 2024 | | 2024 |
| SINGLE-CELL INVESTIGATION OF MERCAPTOPURINE-ASSOCIATED LIVER INJURY K Hoshitsuki, YC Hsiao, M Maillard, X Yang, Q Pan, S Bhatara, W Yang, ... HEPATOLOGY 80, S924-S925, 2024 | | 2024 |
| Genetic variations of CYP450 and ABC transporters associated with trabectedin severe hepatotoxicity in patients with advanced soft--tissue sarcoma: a pharmacogenetic study M Maillard, C Chevreau, F Le Louedec, M Cassou, C Delmas, L Gourdain, ... FUNDAMENTAL & CLINICAL PHARMACOLOGY 35, 86-87, 2021 | | 2021 |
